Publications

5891 Results

Difference in Association of obesity with prostate cancer risk between U.S. African-American and non-Hispanic white men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Authors
W Barrington;J Schenk;R Etzioni;K Arnold;M Neuhouser;IM Thompson;MS Lucia;A Kristal
Journal / Conference
JAMA Oncology 24(4):765
Year
2015
Research Committee(s)
Prevention, Screening, and and Surveillance
PMID
PMID25834168
PMC
PMC4570268
Study Number(s)
S0000

Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial

Authors
T Murtola;B Gurel;M Umbehr;MS Lucia;IM Thompson;P Goodman;A Kristal;H Parnes;SM Lippman;S Sutcliffe;S Peskoe;C Drake;W Nelson;A De Marzo;EA Platz
Journal / Conference
American Urological Association Annual Meeting (May 15-19, 2015, New Orleans, LA), poster, abstract #MP4-02
Year
2015
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Associations of obesity with prostate cancer risk differ between U.S. African-American and non-Hispanic white men: results from the Selenium and Vitamin E Cancer Prevention Trial

Authors
WE Barrington;J Schenk;R Etzioni;K Arnold;M Neuhouser;IM Thompson;MS Lucia;AR Kristal
Journal / Conference
American Society of Preventive Oncology (Mar 14-17, 2015, Birmingham, AL); poster;
Year
2015
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S0000

SWOG 0709: A randomized phase II “pick-the-winner” trial of erlotinib (ERL) vs. ERL plus carboplatin/paclitaxel (C/T) in patients (pts) with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS 2) as selected by serum proteomics

Authors
P Lara;J Moon;P Hesketh;M Redman;SK Williamson;F Hirsch;P Mack;D Gandara
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 8040); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Lung
Study Number(s)
S0709

SWOG S0518: phase III prospective randomized comparison of depot octreotide plus interferon alpha versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127)

Authors
JC Yao;K Guthrie;C Moran;J Strosberg;MH Kulke;J Ang Chan;N Loconte;R McWilliams;EM Wolin;BI Mattar;S McDonough;H Chen;C Blanke;HS Hochster
Journal / Conference
Journal of Clinical Oncology 33:5s, 2015 (suppl; abstr 4004); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
S0518

SWOG S1115: randomized phase II clinical trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX inpatients with metastatic pancreatic cancer after prior chemo- therapy

Authors
V Chung;S McDonough;PA Phillip;D Backlund Cardin;A Wang-Gillam;L Hui;A Lowy;K Guthrie;C Blanke;H Hochster
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 4119); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
S1115

Phase II feasibility study of a physical activity and dietary change weight loss intervention in a subset analysis of breast cancer survivors from SWOG S1008

Authors
H Greenlee;D Lew;J Pierce;L Hansen;V Newman;J Korner;A Sayegh;L Frehrenbacher;S Lo;J Klemp;K Rinn;J Robertson;J Unger;J Gralow;K Albain;R Krouse;C Fabian
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 9572); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Cancer Survivorship
Study Number(s)
S1008

SWOG S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX), capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC)

Authors
CG Leichman;S McDonough;S Smalley;K Billingsley;H Lenz;A Hezel;M Velasco;M Beldner;K Guthrie;C Blanke;H Hochster
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl;abstr 3516); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster discussion;
Year
2015
Research Committee(s)
Gastrointestinal
Study Number(s)
S0713

Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor- (HR) positive and HER2-negative breast cancer: SWOG/NRG/Alliance S1207 (NCT01674140)

Authors
M Chavez-Macgregor;W Barlow;L Pusztai;MP Goetz;P Rastogi;P Ganz;EP Mamouns;S Paik;H Bandos;J Gralow;D Lew;G Hortobagyi
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr TPS637); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;
Year
2015
Research Committee(s)
Breast
Study Number(s)
S1207

SWOG 1107: Parallel randomized phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (pts) with advanced papillary renal cell carcinoma (pRCC)

Authors
P Twardowski;M Plets;ER Plimack;N Aggarwal;C Tangen;N Vogelzang;IM Thompson;PN Lara
Journal / Conference
Journal of Clinical Oncology 33:5s (suppl; abstr 4523); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster discussion;
Year
2015
Research Committee(s)
Genitourinary
Study Number(s)
S1107